Official Title
A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19
Brief Summary

According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.

Completed
COVID-19

Drug: Ciclesonide Metered Dose Inhaler [Alvesco]

Ciclesonide 320ug oral inhalation q12h for 14 days

Eligibility Criteria

Inclusion Criteria:

- Patients with mild COVID-19 (NEWS scoring system 0-4)

- Patient within 7 days from symptom onset or Patient within 48 hous after laboratory
diagnosis (SARS-CoV-2 RT-PCR)

Exclusion Criteria:

- Hypoxia (SaO2 <95%)

- Unable to take oral medication

- Unable to use inhaler

- Pregnancy or breast feeding

- Immunocompromising conditions

- Moderate/severe renal dysfunction : creatinine clearance (CCL) < 30 mL/min

- Moderate/severe liver dysfunction: AST or ALT > 5 times upper normal limit

- Asthma or chronic obstructive lung disease

Eligibility Gender
All
Eligibility Age
Minimum: 19 Years ~ Maximum: 80 Years
Countries
Korea, Republic of
Locations

Korea University Guro Hospital
Seoul, Korea, Republic of

Korea University Guro Hospital
NCT Number
Keywords
SARS-CoV-2
Ciclesonide
Viral load
Coronavirus
MeSH Terms
COVID-19
Ciclesonide